Abstract
Purpose
To evaluate the clinical effect, safety, and administration procedure of slow-release dexamethasone implants (Ozurdex®) for macular edema secondary to retinal vein occlusion in clinical praxis.
Methods
Data from 11 patients (4 eyes with central vein occlusion and 7 eyes with branch vein occlusion) were reviewed. Data were compiled and analyzed with respect to best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and adverse events. Follow-up was 10 months. Changes in BCVA ≥ logMAR 0.2, IOP ≥5 mm Hg, and CMT ≥100 μm were considered clinically relevant.
Results
Two months after the first dexamethasone implant, BCVA improved from logMAR 0.65 ± 0.2 to logMAR 0.34 ± 0.1. All patients demonstrated a decrease in CMT from an initial average value of 632 ± 178 μm to 229 ± 34 μm. However, in 10 out of 11 eyes, macular edema recurred by month 4 through 5 and a second dexamethasone implant was administered. Two and 4 months after the second implant, BCVA was logMAR 0.36 ± 0.2 and logMAR 0.40 ± 0.2 and the CMT was 254 ± 61 μm and 357 ± 81 μm, respectively. The IOP increased 5.1 ± 1.5 mm Hg 1 month after the first implant compared to baseline. In eyes with an IOP above 25 mm Hg (4 out of 11), pressure-lowering eyedrops were administered.
Conclusions
Administration of dexamethasone implants induced a clinically relevant increase in visual acuity and a decrease in central macular thickness. In 91% of patients, macular edema recurred within 5 months and a second implant was administered. Adverse events, primarily increased IOP, were manageable. The injection procedure was relatively simple and uncomplicated.
Keywords
Get full access to this article
View all access options for this article.